Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.6422
-0.0392-5.75%
Post-market: 0.66490.0227+3.53%19:59 EDT
Volume:9.37M
Turnover:6.14M
Market Cap:178.53M
PE:-1.29
High:0.7000
Open:0.6741
Low:0.6345
Close:0.6814
52wk High:2.55
52wk Low:0.5261
Shares:278.00M
Float Shares:245.00M
Volume Ratio:0.56
T/O Rate:3.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:5.71
PE(LYR):-2.49

Loading ...

Humacyte's Bioengineered Blood Vessel Hits Primary Endpoint in Phase 3 Trial

Dow Jones
·
Jun 11

Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall

MT Newswires Live
·
Jun 11

BRIEF-Humacyte, Inc. Announces Proposed Public Offering Of Common Stock

Reuters
·
Jun 11

Humacyte announces V012 study of ATEV meets primary endpoint

TIPRANKS
·
Jun 11

Humacyte announces common stock offering, no amount given

TIPRANKS
·
Jun 11

Humacyte launches underwritten follow-on common stock offering

Reuters
·
Jun 11

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

THOMSON REUTERS
·
Jun 11

Humacyte - to Use Net Proceeds for Symvess Commercialization and Pipeline Development

THOMSON REUTERS
·
Jun 11

Humacyte ATEV beats AV fistula on catheter-free days in interim Phase 3 V012 trial in female dialysis patients

Reuters
·
Jun 11

Humacyte Atev Met Superiority Primary Endpoint Compared to Standard of Care Av Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

THOMSON REUTERS
·
Jun 11

Humacyte - Study Enrollment to Terminate After Meeting Primary Endpoint

THOMSON REUTERS
·
Jun 11

Humacyte - to File Supplemental Bla With FDA in Second Half of 2026

THOMSON REUTERS
·
Jun 11

Humacyte shareholders approve increase in authorized common shares to 550 million

Reuters
·
Jun 10

Humacyte Price Target Maintained With a $2.00/Share by BTIG

Dow Jones
·
Jun 08

Humacyte Is Maintained at Speculative Buy by Benchmark

Dow Jones
·
Jun 01

Humacyte price target raised to $2 from $1 at Benchmark

TIPRANKS
·
Jun 01

Humacyte Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Dow Jones
·
May 27

Humacyte announces presentation at VASA meeting on self-repair ATEV

TIPRANKS
·
May 26

Humacyte says interim Phase 3 dialysis access study results due June 11

Reuters
·
May 26

Humacyte director Kathleen Sebelius acquires 56,818 shares for $49,999.84

Reuters
·
May 21